ANI Pharmaceuticals (ANIP) PT Raised to $103 at Leerink Partners

Leerink Partners analyst Faisal A. Khurshid raised the price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $103.00 (from $100.00) while maintaining a Outperform rating.

The analyst comments "We think a beat-and-raise for ANIP's Cortrophin Gel is likely based on the Q/Q script trends. Ahead of ANIP's 3Q25 earnings, we refresh our analysis of scripts data for Cortrophin and MNK's (Not Rated) Acthar Gel. Consensus for Cortrophin revs is $93M, and we think a 10% beat (i.e., >$100M on the quarter) is possible based on our analysis. If achieved, we believe ANIP will need to raise FY25 Cortrophin guidance to >$330M. Recall ANIP's business includes a generics business on track for >$400M in 2025 revs and a branded/specialty business on track for > $400M in 2025 revs, with Cortrophin as the star product. See our analysis within, our past analysis HERE and 2Q25 earnings recap HERE. Reiterate OP; PT to $103."

You May Also Be Interested In

• JPMorgan Downgrades ASX Limited (ASX:AU) (ASXFY) to Neutral
• Jefferies Starts Aehr Test Systems (AEHR) at Buy
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c